Biosplice Therapeutics, Inc. (formerly Samumed, LLC) is a private biopharmaceutical company based in San Diego, California.It was founded in 2008 by Osman Kibar.. Samumed's products in development target novel components of the Wnt signaling pathway. We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice, said Cevdet Samikoglu, Chief Executive Officer of Biosplice. Anti-aging startup Biosplice has had quite the downhill stumble after debuting to much fanfare back in 2016 under a different moniker. 1985 - 2023 BioSpace.com. You can also learn more about how to sell your private shares before getting started. Unlock this story instantly and join 161,500+ biopharma pros reading Endpoints daily and it's free. Learn more about Biosplice Therapeutics stock Updated on: Jun 12, 2022 Register for Details The shot raked in more than $18 billion last year and saved millions of lives. Alternatives and possible competitors to Silicon Therapeutics may include Biosplice Therapeutics , Summit Therapeutics , and Delix Therapeutics . Biosplice Therapeutics (formerly Samumed) "Biosplice's mission is to restore health by delivering first-in-class therapies that harness alternative splicing.". Ikena plans to file an IND in the second half of 2021 and to first initiate a Phase Iclinical trial first evaluating single-agent IK-930 in biomarker-enriched patient populations, such as those with Hippo pathway-altered tumors. Some like Sana Biotechnology (SANA -0.81%) are still in preclinical. SaaS, Android, Cloud Computing, Medical Device), Where the organization is headquartered (e.g. Bioscience & Technology Business CenterThe University of KansasLawrence, Kansas. Brian, are there any of these that you think investors should want to have on their radar? Learn More. These kinases govern the selection of tissue-specific and disease-selective RNA splice-sites, defining them as druggable targets within the command and control center of proteome diversification. Learn more at https://www.biosplice.com, Corporate Contact:Erich HorsleyBiosplice Therapeutics, [email protected]. Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. Intra-articular (IA) injection into either knee with a therapeutic aim including, but not limited to, hyaluronic acid, platelet-rich plasma (PRP), and stem cell therapies within 26 weeks prior to Day 1 or IA glucocorticoids within 12 weeks prior to Day 1 The biotech boom in the early days of the pandemic helped fuel the rise of Taysha Gene Therapies and Jaguar Gene Therapy, but the winter freeze that followed has also caused a hunkering down for the biotechs, chaired by ex-AveXis CEO Sean Nolan. When he told a group of senior scientists about his ideas for drug delivery at a Chinese restaurant in 1979, one of them blew cigar smoke in his face. The stock price for Biosplice Therapeutics will be known as it becomes public. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services. SAN DIEGO, April 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA. His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. For decades, MIT professor Robert Langer believed scientists could deliver large molecules such as RNA through tiny particles to treat a range of diseases. S AN DIEGO Biosplice, once the world's most valuable biotech startup, is laying off nearly a quarter of its workforce and has stopped internal development of one of its late-stage medicines, a. We did that for obvious reasons, CFO and CBO Erich Horsley told Endpoints News. Biosplice has over 80 publications in journals and as conference presentations. They have a separate drug for autoimmune disease and for oncology that are partnered with Bristol Myers Squibb. Other disorders the company will target with its GeneTac platform will include myotonic dystrophy type-1, and other indications that have yet to be publicly announced. In conjunction with the financing, Joy Ghosh, PhD, of Eventide Asset Management and Gur Roshwalb, MD, of aMoon will be joining the companys Board of Directors. Each of these companies announced their intentions this week. www.biosplice.com Formerly Known As Wintherix & Epitherix, Samumed Ownership Status Privately Held (backing) Financing Status Private Equity-Backed Primary Industry Drug Discovery Other Industries Biotechnology Pharmaceuticals Primary Office 9360 Towne Centre Drive San Diego, CA 92121 United States +1 (858) 000-0000 As much promise as I want to give to Sana's pipeline, I have a hard time getting to the $3.4 billion valuation. one-time use only and expires after 24 hours. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*. You better start looking for another job, the scientist said. Now, the biotech is laying off a large swath of its staff as it undergoes a pipeline overhaul. one-time use only and expires after 24 hours. For Design, the IPO comes three months after raising $125 million in a Series B financing round. They also plan to go public with an IPO this year. Please note this link is one-time use only and is valid for only 24 hours. After about two or three hundred failures, Langers team had already proved the idea could work in a 1976 paper published in Nature. The data in the tables and charts is based on data from public sources and although we make every effort to compile the data, it may not coincide with the actual data of the issuer. SAN DIEGO and CHENGDU, China, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. ("Biosplice"), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK . Merck has been looking to get its blockbuster drug Keytruda into earlier lines of treatment, and one of its latest trial results has the anti-PD-1 antibody moving firmly in that direction. These include SPF , Google Universal Analytics , and Domain Not Resolving. It's already testing its drug called CAN-2409 in prostate cancer, and then it's planning phase 3 for brain cancer next year. About Mammoth Biosciences Stock. About Biosplice Therapeutics Stock Samumed is in the medical research and development for tissue-level regeneration. Biosplices target class governs the selection of tissue-specific mRNA splice sites, making them attractive, druggable targets within the cellular command and control center. Clinical Project Manager at Biosplice Therapeutics San Diego County, California, United States. The program with Bristol Myers Squibb is targeting STAT3. Active, Closed, Last funding round type (e.g. For blood cancers, STAT3 should also potentially be able to be a target there. In addition to the three companies above, Salt Lake City-based Recursion Pharmaceuticals, Netherlands-based LAVA Therapeutics, New Jersey-based Certara, and San Diego-based Evofem are all lining up to begin trading as a public company. Alternative splicing is an essential biological mechanism that regulates the diversification of proteins in a cell, which, in turn, determines cell type and function. Biosplice Therapeutics is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. I did find one that has filed an S-1, Candel Therapeutics, that's in phase 3 development; it's using nonreplicating virus to attack tumors. Biosplice's drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer's disease to. Tom Jones take zinc after sex or personal release. The company started in 2015 and is . . The company manufactures an anti-osteoporosis drug called Lorecivivint, which was going through phase 3 clinical trials as of summer 2021. The Motley Fool owns shares of and recommends Bristol Myers Squibb. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. CIOs and business technology executives at this event will also discuss how men Shanghai Everest Medicines in-licensed a BTK inhibitor for renal diseases from Sinovent and SinoMab Bio for $561 mln. About BiospliceBiosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. We'll e-mail you a link to set a new password. Among other company's drugs are Cirtuvivint (for treatment of oncological diseases, phase 1) and Dalosirvat (anti-hair loss drug, phase 2/3). Jan 3, 2023 06:30am. *Average returns of all recommendations since inception. Ikena Oncology, a company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, begins trading on the Nasdaq at $16 per share. Novartis can't make enough of it, A gene editing 3.0 player goes deep on cash, frontier science to put precision epigenetics to the big test, Decades after breakthrough, scientists still puzzling over mRNA delivery, Following the government's lead, Lilly caps out-of-pocket costs for insulin at $35 per month, Cell therapy biotech from Stanford CAR-T leader Crystal Mackall nabs $200M for PhII, Ex-AveXis crew trims staff at Chicago-area Jaguar Gene Therapy, Keytruda hits one primary endpoint for use before and after surgery in lung cancer, Amicus eyes Pompe approval; Atea ends Dengue work; 2seventy, Travere line up offerings. In this Motley Fool Live video recorded on June 30, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss two upcoming biotech stock IPOs you'll want to have on your radar. Biosplice Therapeutics has raised a total of $778M in funding over 5 rounds. We are delighted to align with our new investors and board behind the immense therapeutic potential of Biosplice, said Cevdet Samikoglu, Chief Executive Officer of Biosplice. Biosplice Therapeutics is an American pharmaceutical company engaged in the development of alternative splicing technologies. About BiospliceBiosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. SAN DIEGO and CHENGDU, China, Sept. 15, 2021 -- Biosplice Therapeutics, Inc. , a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major. San Diego, California, United States. Integrating digital therapeutics early in the asset development process will allow for gathering of clinical data to drive a clearer value proposition that maximizes the potential of both products See our Risk Factors for a more detailed explanation of the risks involved by investing through EquityZens platform. All trademarks, logos and company names are the property of their respective owners. Amicus said last October the FDA wasnt able to do the required inspection of its manufacturing partner, WuXi Biologics in China, during the review timeframe because of restrictions on travel related to the pandemic. 10 stocks we like better than Bristol Myers SquibbWhen our award-winning analyst team has a stock tip, it can pay to listen. Join to view profile Biosplice Therapeutics . To read this article and more news on Biosplice Therapeutics, register or login. Check the background of this firm on FINRAs BrokerCheck. Cost basis and return based on previous market day close. Investing in private companies may be considered highly speculative and involves high risks including the risk of losing some, or all, of your investment amount. When developed in combination with a medicinal asset, digital therapeutics enable significant market differentiation and significant benefits for stakeholdersfrom optimizing patient outcomes to supporting more efficient generation of compelling real-world data Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the fourth quarter and full year ended December 31, 2022. Eli Lilly is looking to get ahead of any more federal action on insulin prices, announcing today that it will not only slash its most commonly used insulin by 70%, but cap out-of-pocket costs for those on commercial insurance at $35 per month just as the federal government recently did for those insured by Medicare. Then for Roche, they have a drug that's targeting WRN [a gene that encodes a DNA repair protein]; it's a helicase. Corporate Contact: Erich Horsley Biosplice Therapeutics, Inc. Unlock this article along with other benefits by subscribing to one of our paid plans. Brief Summary: This phase 3 study is a multicenter, randomized, double-blind, placebo-controlled study of lorecivivint injected intraarticularly (IA) into the target knee (most painful) joint of moderately to severely symptomatic osteoarthritis (OA) subjects at a single dose of 0.07 mg lorecivivint per 2 mL injection. X0002 is . Catherine Stehman-Breen, Chroma Medicine CEO, David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images), Hemolytic Anemia Sales Specialist, Rare Genetic Diseases, Osman Kibar lays down his hand at Samumed, stepping away from CEO role as his once-heralded anti-aging biotech rebrands, Digital therapeutics: The key to maximizing the potential of medicinal assets, A radioactive prostate cancer therapy is a last lifeline for patients. The stick will trade under the ticker symbol IKNA.. Media Contact: Andrea Sampson, Sampson PR Group [email protected], 562-304-0301 Investor Contact: Jody Cain, LHA Investor Relations [email protected], 310-691-7100 They have two partners at Bristol Myers Squibb ( BMY -1.71%) and Roche [Holding] ( RHHBY -2.31%). Samumed made quite the entrance back in 2016, when it launched with some anti-aging programs and a whopping $12 billion valuation. Persons. Its scientific platform is based on biological discoveries that govern tissue specialization and enable it to selectively eliminate harmful proteins using small molecules. 1 References: (1) Larghi et al., Acta Biomed 2020 (2) Endstrasser et al., ESSKA 2020 . Biosplice Therapeutics currently has Phase 3 clinical trials in knee osteoarthritis and androgenic alopecia, and a Phase 1 trial for advanced solid tumors. Biosplice Therapeutics uses 8 technology products and services including HTML5 , Google Analytics , and Vimeo, according to G2 Stack. They say everything is great, no problems. Learn more at https://www.biosplice.com. The information provided on Xipometer.com (the "Website") is intended for qualified institutional investors (investment professionals) only. Biosplice Therapeutics, Inc. And then if they knock out or block the activity of WRN, then the tumors can't repair those mutations that they're making, and then hopefully the tumor will just die. Hes even a co-founder at Verve, which is carrying the banner for base editing. Biosplice's drugs in clinical development include lorecivivint for osteoarthritis (in Phase 3), cirtuvivint for numerous cancers, and a broad pipeline that ranges from Alzheimer's disease to other degenerative conditions. SM04554 Disappears From Biosplice's Website (9/7/21) . Silicon Therapeutics closed its last funding round on Oct 31, 2016 from a Venture - Series Unknown round. Equity securities are offered through EquityZen Securities. Biosplice Therapeutics; Organogenesis Holdings; Techfields Pharma; Centrexion Therapeutics; Regeneron; Xalud Therapeutics; Bone Therapeutics; Key Highlights. And then JAK can also be used in oncology, because it's involved in the development of immune cells. Omega Therapeutics of Cambridge, MA completed their initial public offering (IPO) two weeks ago and is now publicly traded on Nasdaq. Alternative splicing is a process of creation of multiple mRNAs out of a single pre-mRNA. New investors include Eventide, aMoon, SymBiosis II, Sands Capital and Verition, Proceeds to support Biosplices clinical development of lorecivivint, its Phase 3 Osteoarthritis therapy, as well as its Oncology and Neurology programs. To make the world smarter, happier, and richer. If you're already an Endpoints subscriber, enter your email below for a The move to again slash the cost of insulin back in 2019, Lilly cut the list price of Humalog by 50% comes as rationing of the life-saving shot has led to deaths for some diabetics who could not afford their injections, even as Congress is working on another push to cap out-of-pocket costs for diabetics after Senate Republicans shot down the idea last August. They just revealed what they believe are the ten best stocks for investors to buy right now and Bristol Myers Squibb wasn't one of them! Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. Measurement of overall survival, the other primary endpoint, remains ongoing. Making the world smarter, happier, and richer. Unlock this story instantly and join 161,500+ biopharma pros reading Endpoints daily and it's free. magic link that lets you log in quickly without using a password. After Novartis acquired AveXis, executives from the leading gene therapy biotech shuffled off to form new startups looking to repeat their Zolgensma story for other diseases. Details of the startup: Valuation: $12.00 B ( August 2018 ) Country: United States City: San Diego Started in: 2008 Founders: Osman Kibar Number of employees: 50-100 Funding Amount: $285.71M Anytime we're talking about extended survival, that's the gold standard for cancer. After Novartis acquired AveXis, executives from the leading gene therapy biotech shuffled off to form new startups looking to repeat their Zolgensma story for other diseases. Gerostate Alpha raising $500k through WeFunder (Live Now). Conversely, dysregulated alternative splicing can be a root cause of developmental disorders, tissue degeneration and cancer. Biosplice Therapeutics is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre . We'll e-mail you a link to set a new password. In September 2020, Sorrento Therapeutics released positive Phase 1b trial data (clinicaltrials.gov NCT03542838) of resiniferatoxin (RTX) in the reduction of OsteoArthritis (OA) knee pain. That level of fanfare was nowhere to be found on Thursday, when. San Francisco Bay Area, Silicon Valley), Operating Status of Organization e.g. Finances from the IPO, as well as the cash from the Series B, will be used to develop treatments for nucleotide repeat expansion disorders, including its lead program in Friedreich ataxia, which is expected to enter clinical development in the first half of 2022. AT-GAA consists of biologic cipaglucosidase alfaand miglustat, a stabilizer of the biologic. Digital therapeutics support increased access to safe and effective therapies, providing an untapped opportunity for biopharmaceutical companies to maximize the value of medicinal assets and drive differentiation In finance, a unicorn is a privately held startup company with a current valuation of US$1 billion or more, across technology centers throughout the world.. Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing. Alternative splicing regulates genome potential by differentially joining or skipping gene segments at alternative splice sites. *** - To view the data, please log into your account or create a new one. Design said it expects to raise approximately $240 million from the IPO, a little bit higher than the $228 million the company previously anticipated. Biosplice Therapeutics is funded by 11 investors. Who are Silicon Therapeutics 's competitors? His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug. This investment round positions us to accelerate the development and launch of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis. By registering, you agree to Forges Terms of Use. They say they will not only cure arthritis, but also cancer in the future with their amazing technology. That's especially the case with biotech stocks that go public. Both Moffitt Cancer Center and Mayo Clinic in Florida, not too far from Domingos and his family, said he would have to wait between three and a half and four months to get the treatment. Please note the magic link is Alternative splicing is a process of creation of multiple mRNAs out of a single pre-mRNA. That's in the same pathway as JAK, which we've talked about a lot. This investment round positions us to accelerate the development and launch of lorecivivint, our groundbreaking Phase 3 program in osteoarthritis. Biosplice Therapeutics, Inc. [email protected] 858-365-0200. The company is headquartered in San Diego, California. https://www.streetinsider.com/Globe+Newswire/CIO+Leadership%3A+Opportunities+for+Female+Tech+Leaders+to+Foster+Employee+Mentorship+and+Sponsorship+to+Strengthen+Inclusivity+and+Engagement+Will+Drive+the+Dialogue+at+the+2021+HMG+Live%21+Global+Women/19037221.html, https://seekingalpha.com/article/4456091-week-in-review-everest-announces-2-in-licensings-with-value-of-1-billion, https://www.benzinga.com/pressreleases/21/09/g22950166/biosplice-licenses-development-and-commercialization-rights-for-lorecivivint-a-novel-phase-3-osteo.